Insight Molecular Diagnostics
IMDX
50 hedge funds and large institutions have $63.7M invested in Insight Molecular Diagnostics in 2019 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 12 increasing their positions, 1 reducing their positions, and 2 closing their positions.
1,400% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 2
1,100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 1
455% more capital invested
Capital invested by funds: $11.5M → $63.7M (+$52.2M)
127% more funds holding
Funds holding: 22 → 50 (+28)
0.53% more ownership
Funds ownership: 1.02% → 1.55% (+0.53%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$8.03M |
| 2 |
RI
RTW Investments
New York
|
+$4.16M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.96M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.8M |
| 5 |
BC
Broadwood Capital
New York
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$17K |
| 2 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$709 |
IMDX Hedge Fund Activity: Q1 2019 in Review
50 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2019, worth a combined $63.7M — up 455% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IMDX positions and 2 closed out — a net gain of 28 holders — while 12 added to existing stakes and 1 trimmed.
The largest buyer was Emerald Mutual Fund Advisers Trust, opening a new position worth an estimated $8.03M. The largest seller was Janney Montgomery Scott, exiting entirely with an estimated $17K sold.
- 50 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2019, up from 22 in Q4 2018.
- Funds reported $63.7M of Insight Molecular Diagnostics stock for Q1 2019, up 455% quarter-over-quarter.
- 30 funds opened new Insight Molecular Diagnostics positions in Q1 2019 and 2 closed out, a net change of +28 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2019 was Emerald Mutual Fund Advisers Trust, an estimated $8.03M added.
- The largest Insight Molecular Diagnostics seller in Q1 2019 was Janney Montgomery Scott, an estimated $17K sold.
Based on aggregated 13F filings for Q1 2019.